Risk of bearing joint research costs with universities and public research institutions
First written in FY2017. 7 of 8 entries say "Restated". Latest entry: FY2023-Q3.
3 other companies' latest entry also says "Restated".
- FY2023-Q3RestatedAnnual report
「During the cumulative third-quarter period, there were no new business risks and no material changes in the business risks described in the annual securities report for the preceding fiscal year.」
Discloses that there have been no material changes regarding the risk of bearing joint research costs with universities and public research institutions. - FY2020RestatedAnnual report
「The Company intends to continue actively pursuing joint research with universities and public research institutions and plans to bear a corresponding share of the joint research costs. However, if circumstances such as the research themes result in the Company incurring costs that were not anticipated, this may affect its operating results.」
Continues to disclose the risk of additional and unplanned cost burdens associated with expanding joint research with universities and public research institutions. - FY2019RestatedAnnual report
「The Company intends to continue actively pursuing joint research with universities and public research institutions and plans to bear a corresponding share of the joint research costs. However, if circumstances such as the research themes result in the Company incurring costs that were not anticipated, this may affect its operating results.」
Continues to disclose the risk of additional and unplanned cost burdens associated with expanding joint research with universities and public research institutions. - FY2019-Q1RestatedAnnual report
「During the cumulative first-quarter period, there were no new business or other risks and no material changes to the business or other risks described in the annual securities report for the previous fiscal year.」
Discloses that there have been no material changes regarding the risk of bearing joint research costs with universities and public research institutions. - FY2018RestatedAnnual report
「The Company intends to continue actively pursuing joint research with universities and public research institutions and plans to bear a corresponding share of the joint research costs. However, if circumstances such as the research themes result in the Company incurring costs that were not anticipated, this may affect its operating results.」
Continues to disclose the risk of additional and unplanned cost burdens associated with expanding joint research with universities and public research institutions. - FY2018-Q3RestatedAnnual report
「During the nine months ended September, there were no new business or other risks, nor any material changes to the business or other risks described in the securities report for the prior fiscal year.」
Discloses that there have been no material changes regarding the risk of bearing joint research costs with universities and public research institutions. - FY2018-Q2RestatedAnnual report
「During the six months ended June, there were no new business or other risks, nor any material changes to the business or other risks described in the securities report for the prior fiscal year.」
Discloses that there have been no material changes regarding the risk of bearing joint research costs with universities and public research institutions. - FY2017First statedAnnual report
「The Company intends to continue actively pursuing joint research with universities and public research institutions and plans to bear a corresponding share of the joint research costs. However, if circumstances such as the research themes result in the Company incurring costs that were not anticipated, this may affect its operating results.」
The risk of additional and unplanned cost burdens associated with expanding joint research with universities and public research institutions is disclosed for the first time.